The interaction of the immune check inhibitors (ICI) with the PD-1, PD-L1, and CTLA-4 in the tissues leads to a disruption of the host T-cell signaling and the upregulation of the T-cell immune response against cancer cells. Here, CD274 is linked to cancer.